#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Designed scaffolds should be biocompatible and biodegradable , capable of producing an extracellular matrix ( ECM ) by supporting the cell ’s adhesion and proliferation .
2-1	16-24	Designed	object[2]	new[2]	ana	3-1[0_2]
2-2	25-34	scaffolds	object[2]	new[2]	_	_
2-3	35-41	should	_	_	_	_
2-4	42-44	be	_	_	_	_
2-5	45-58	biocompatible	_	_	_	_
2-6	59-62	and	_	_	_	_
2-7	63-76	biodegradable	_	_	_	_
2-8	77-78	,	_	_	_	_
2-9	79-86	capable	_	_	_	_
2-10	87-89	of	_	_	_	_
2-11	90-99	producing	_	_	_	_
2-12	100-102	an	substance[3]	new[3]	_	_
2-13	103-116	extracellular	substance[3]	new[3]	_	_
2-14	117-123	matrix	substance[3]	new[3]	_	_
2-15	124-125	(	_	_	_	_
2-16	126-129	ECM	abstract	new	_	_
2-17	130-131	)	_	_	_	_
2-18	132-134	by	_	_	_	_
2-19	135-145	supporting	_	_	_	_
2-20	146-149	the	abstract[6]|abstract[7]	new[6]|new[7]	coref|coref	6-13[43_6]|14-12[132_7]
2-21	150-154	cell	place[5]|abstract[6]|abstract[7]	new[5]|new[6]|new[7]	coref	4-45[0_5]
2-22	155-157	’s	place[5]|abstract[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
2-23	158-166	adhesion	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-24	167-170	and	abstract[7]	new[7]	_	_
2-25	171-184	proliferation	abstract[7]|event	new[7]|new	coref	4-45[29_0]
2-26	185-186	.	_	_	_	_

#Text=They should also have porosity to promote nutrient transportation , and their mechanical properties should be similar to native tissue .
3-1	187-191	They	object	giv	ana	3-12
3-2	192-198	should	_	_	_	_
3-3	199-203	also	_	_	_	_
3-4	204-208	have	_	_	_	_
3-5	209-217	porosity	substance	new	_	_
3-6	218-220	to	_	_	_	_
3-7	221-228	promote	_	_	_	_
3-8	229-237	nutrient	substance|abstract[12]	new|new[12]	coref	4-33
3-9	238-252	transportation	abstract[12]	new[12]	_	_
3-10	253-254	,	_	_	_	_
3-11	255-258	and	_	_	_	_
3-12	259-264	their	object|abstract[14]	giv|new[14]	coref|coref	5-8|12-3[93_14]
3-13	265-275	mechanical	abstract[14]	new[14]	_	_
3-14	276-286	properties	abstract[14]	new[14]	_	_
3-15	287-293	should	_	_	_	_
3-16	294-296	be	_	_	_	_
3-17	297-304	similar	_	_	_	_
3-18	305-307	to	_	_	_	_
3-19	308-314	native	object[15]	new[15]	coref	12-7[0_15]
3-20	315-321	tissue	object[15]	new[15]	_	_
3-21	322-323	.	_	_	_	_

#Text=To meet these requirements , a high surface area and an interconnected three-dimensional ( 3D ) porous structure with sizes ranging between 200 and 600 μm are essential , while also providing nutrient transfer , waste disposal , cellular infiltration , neovascularization , and cell proliferation .
4-1	324-326	To	_	_	_	_
4-2	327-331	meet	_	_	_	_
4-3	332-337	these	abstract[16]	new[16]	_	_
4-4	338-350	requirements	abstract[16]	new[16]	_	_
4-5	351-352	,	_	_	_	_
4-6	353-354	a	abstract[18]	new[18]	_	_
4-7	355-359	high	abstract[18]	new[18]	_	_
4-8	360-367	surface	place|abstract[18]	new|new[18]	_	_
4-9	368-372	area	abstract[18]	new[18]	_	_
4-10	373-376	and	_	_	_	_
4-11	377-379	an	abstract[20]	new[20]	_	_
4-12	380-394	interconnected	abstract[20]	new[20]	_	_
4-13	395-412	three-dimensional	abstract[20]	new[20]	_	_
4-14	413-414	(	abstract[20]	new[20]	_	_
4-15	415-417	3D	abstract|abstract[20]	new|new[20]	_	_
4-16	418-419	)	abstract[20]	new[20]	_	_
4-17	420-426	porous	abstract[20]	new[20]	_	_
4-18	427-436	structure	abstract[20]	new[20]	_	_
4-19	437-441	with	abstract[20]	new[20]	_	_
4-20	442-447	sizes	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-21	448-455	ranging	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-22	456-463	between	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-23	464-467	200	abstract[20]|abstract[21]|event[22]	new[20]|new[21]|new[22]	_	_
4-24	468-471	and	abstract[20]|abstract[21]|event[22]	new[20]|new[21]|new[22]	_	_
4-25	472-475	600	abstract[20]|abstract[21]|event[22]	new[20]|new[21]|new[22]	_	_
4-26	476-478	μm	abstract[20]|abstract[21]|event[22]	new[20]|new[21]|new[22]	_	_
4-27	479-482	are	_	_	_	_
4-28	483-492	essential	_	_	_	_
4-29	493-494	,	_	_	_	_
4-30	495-500	while	_	_	_	_
4-31	501-505	also	_	_	_	_
4-32	506-515	providing	_	_	_	_
4-33	516-524	nutrient	substance|abstract[24]	giv|new[24]	_	_
4-34	525-533	transfer	abstract[24]	new[24]	_	_
4-35	534-535	,	_	_	_	_
4-36	536-541	waste	abstract[25]	new[25]	_	_
4-37	542-550	disposal	abstract[25]	new[25]	_	_
4-38	551-552	,	_	_	_	_
4-39	553-561	cellular	abstract[26]	new[26]	_	_
4-40	562-574	infiltration	abstract[26]	new[26]	_	_
4-41	575-576	,	_	_	_	_
4-42	577-595	neovascularization	substance	new	_	_
4-43	596-597	,	_	_	_	_
4-44	598-601	and	_	_	_	_
4-45	602-606	cell	place|event[29]	giv|giv[29]	coref|coref	5-18|14-16[133_29]
4-46	607-620	proliferation	event[29]	giv[29]	_	_
4-47	621-622	.	_	_	_	_

#Text=Natural polymers are preferred materials for producing scaffolds , due to their better overall interactions with various cell types , and their lack of toxicity .
5-1	623-630	Natural	substance[30]	new[30]	coref	5-4[31_30]
5-2	631-639	polymers	substance[30]	new[30]	_	_
5-3	640-643	are	_	_	_	_
5-4	644-653	preferred	substance[31]	giv[31]	ana	5-12[0_31]
5-5	654-663	materials	substance[31]	giv[31]	_	_
5-6	664-667	for	substance[31]	giv[31]	_	_
5-7	668-677	producing	substance[31]	giv[31]	_	_
5-8	678-687	scaffolds	substance[31]|object	giv[31]|giv	_	_
5-9	688-689	,	substance[31]	giv[31]	_	_
5-10	690-693	due	substance[31]	giv[31]	_	_
5-11	694-696	to	substance[31]	giv[31]	_	_
5-12	697-702	their	substance[31]|substance|abstract[34]	giv[31]|giv|new[34]	ana	5-22
5-13	703-709	better	substance[31]|abstract[34]	giv[31]|new[34]	_	_
5-14	710-717	overall	substance[31]|abstract[34]	giv[31]|new[34]	_	_
5-15	718-730	interactions	substance[31]|abstract[34]	giv[31]|new[34]	_	_
5-16	731-735	with	substance[31]|abstract[34]	giv[31]|new[34]	_	_
5-17	736-743	various	substance[31]|abstract[34]|place[36]	giv[31]|new[34]|new[36]	_	_
5-18	744-748	cell	substance[31]|abstract[34]|place|place[36]	giv[31]|new[34]|giv|new[36]	coref	6-13
5-19	749-754	types	substance[31]|abstract[34]|place[36]	giv[31]|new[34]|new[36]	_	_
5-20	755-756	,	substance[31]	giv[31]	_	_
5-21	757-760	and	substance[31]	giv[31]	_	_
5-22	761-766	their	substance[31]|substance|abstract[38]	giv[31]|giv|new[38]	coref	6-3[40_0]
5-23	767-771	lack	substance[31]|abstract[38]	giv[31]|new[38]	_	_
5-24	772-774	of	substance[31]|abstract[38]	giv[31]|new[38]	_	_
5-25	775-783	toxicity	substance[31]|abstract[38]|abstract	giv[31]|new[38]|new	_	_
5-26	784-785	.	_	_	_	_

#Text=However , synthetic polymers are cheaper and allow chemical functionalization to assist cell adhesion despite the immune response .
6-1	786-793	However	_	_	_	_
6-2	794-795	,	_	_	_	_
6-3	796-805	synthetic	substance[40]	giv[40]	coref	7-1[45_40]
6-4	806-814	polymers	substance[40]	giv[40]	_	_
6-5	815-818	are	_	_	_	_
6-6	819-826	cheaper	_	_	_	_
6-7	827-830	and	_	_	_	_
6-8	831-836	allow	_	_	_	_
6-9	837-845	chemical	abstract[41]	new[41]	_	_
6-10	846-863	functionalization	abstract[41]	new[41]	_	_
6-11	864-866	to	_	_	_	_
6-12	867-873	assist	_	_	_	_
6-13	874-878	cell	place|abstract[43]	giv|giv[43]	coref|coref	8-12|14-12[131_43]
6-14	879-887	adhesion	abstract[43]	giv[43]	_	_
6-15	888-895	despite	_	_	_	_
6-16	896-899	the	event[44]	new[44]	_	_
6-17	900-906	immune	event[44]	new[44]	_	_
6-18	907-915	response	event[44]	new[44]	_	_
6-19	916-917	.	_	_	_	_

#Text=The preferred synthetic polymers used for scaffold synthesis include poly(l-lactic acid ) ( PLLA ) , poly(glycolic acid ) ( PGA ) , poly(caprolactone ) ( PCL ) , and poly(lactic- co -glycolic ) acid ( PLGA ) .
7-1	918-921	The	substance[45]	giv[45]	coref	8-3[60_45]
7-2	922-931	preferred	substance[45]	giv[45]	_	_
7-3	932-941	synthetic	substance[45]	giv[45]	_	_
7-4	942-950	polymers	substance[45]	giv[45]	_	_
7-5	951-955	used	substance[45]	giv[45]	_	_
7-6	956-959	for	substance[45]	giv[45]	_	_
7-7	960-968	scaffold	substance[45]|abstract|abstract[47]	giv[45]|new|new[47]	_	_
7-8	969-978	synthesis	substance[45]|abstract[47]	giv[45]|new[47]	_	_
7-9	979-986	include	_	_	_	_
7-10	987-1000	poly(l-lactic	substance[48]	new[48]	_	_
7-11	1001-1005	acid	substance[48]	new[48]	_	_
7-12	1006-1007	)	_	_	_	_
7-13	1008-1009	(	_	_	_	_
7-14	1010-1014	PLLA	abstract	new	_	_
7-15	1015-1016	)	_	_	_	_
7-16	1017-1018	,	_	_	_	_
7-17	1019-1032	poly(glycolic	abstract|substance[51]	new|new[51]	appos	7-21[0_51]
7-18	1033-1037	acid	substance[51]	new[51]	_	_
7-19	1038-1039	)	_	_	_	_
7-20	1040-1041	(	_	_	_	_
7-21	1042-1045	PGA	substance	giv	_	_
7-22	1046-1047	)	_	_	_	_
7-23	1048-1049	,	_	_	_	_
7-24	1050-1067	poly(caprolactone	substance	new	_	_
7-25	1068-1069	)	_	_	_	_
7-26	1070-1071	(	_	_	_	_
7-27	1072-1075	PCL	abstract	new	_	_
7-28	1076-1077	)	_	_	_	_
7-29	1078-1079	,	_	_	_	_
7-30	1080-1083	and	_	_	_	_
7-31	1084-1096	poly(lactic-	abstract|substance[57]	new|new[57]	_	_
7-32	1097-1099	co	abstract|substance[57]	new|new[57]	_	_
7-33	1100-1109	-glycolic	substance[57]	new[57]	_	_
7-34	1110-1111	)	substance[57]	new[57]	_	_
7-35	1112-1116	acid	substance[57]	new[57]	_	_
7-36	1117-1118	(	_	_	_	_
7-37	1119-1123	PLGA	abstract	new	_	_
7-38	1124-1125	)	_	_	_	_
7-39	1126-1127	.	_	_	_	_

#Text=Composites with natural polymers are also available with better hydrophilicity , cell attachment , and biodegradability .
8-1	1128-1138	Composites	substance[59]	new[59]	_	_
8-2	1139-1143	with	substance[59]	new[59]	_	_
8-3	1144-1151	natural	substance[59]|substance[60]	new[59]|giv[60]	coref	15-4[136_60]
8-4	1152-1160	polymers	substance[59]|substance[60]	new[59]|giv[60]	_	_
8-5	1161-1164	are	_	_	_	_
8-6	1165-1169	also	_	_	_	_
8-7	1170-1179	available	_	_	_	_
8-8	1180-1184	with	_	_	_	_
8-9	1185-1191	better	abstract[61]	new[61]	_	_
8-10	1192-1206	hydrophilicity	abstract[61]	new[61]	_	_
8-11	1207-1208	,	_	_	_	_
8-12	1209-1213	cell	place|abstract[63]	giv|new[63]	coref	14-13
8-13	1214-1224	attachment	abstract[63]	new[63]	_	_
8-14	1225-1226	,	_	_	_	_
8-15	1227-1230	and	_	_	_	_
8-16	1231-1247	biodegradability	abstract	new	coref	12-16
8-17	1248-1249	.	_	_	_	_

#Text=The most used biopolymers are chitosan , alginate ( Alg ) , collagen ( Col ) , gelatin ( Gn ) , silk fibroin ( SF ) , and glycosaminoglycans ( GAGs ) .
9-1	1250-1253	The	substance[65]	new[65]	coref	9-6[0_65]
9-2	1254-1258	most	substance[65]	new[65]	_	_
9-3	1259-1263	used	substance[65]	new[65]	_	_
9-4	1264-1275	biopolymers	substance[65]	new[65]	_	_
9-5	1276-1279	are	_	_	_	_
9-6	1280-1288	chitosan	substance|substance[67]	giv|giv[67]	coref|coref	9-6[67_0]|10-1[0_67]
9-7	1289-1290	,	substance[67]	giv[67]	_	_
9-8	1291-1299	alginate	substance[67]|substance	giv[67]|new	appos	9-10
9-9	1300-1301	(	substance[67]	giv[67]	_	_
9-10	1302-1305	Alg	substance[67]|substance	giv[67]|giv	_	_
9-11	1306-1307	)	substance[67]	giv[67]	_	_
9-12	1308-1309	,	substance[67]	giv[67]	_	_
9-13	1310-1318	collagen	substance[67]|organization	giv[67]|new	_	_
9-14	1319-1320	(	substance[67]	giv[67]	_	_
9-15	1321-1324	Col	substance[67]|person	giv[67]|new	_	_
9-16	1325-1326	)	substance[67]	giv[67]	_	_
9-17	1327-1328	,	substance[67]	giv[67]	_	_
9-18	1329-1336	gelatin	substance[67]|substance	giv[67]|new	_	_
9-19	1337-1338	(	substance[67]	giv[67]	_	_
9-20	1339-1341	Gn	substance[67]|abstract	giv[67]|new	_	_
9-21	1342-1343	)	substance[67]	giv[67]	_	_
9-22	1344-1345	,	substance[67]	giv[67]	_	_
9-23	1346-1350	silk	substance[67]|substance|object[75]	giv[67]|new|new[75]	_	_
9-24	1351-1358	fibroin	substance[67]|object[75]	giv[67]|new[75]	_	_
9-25	1359-1360	(	substance[67]	giv[67]	_	_
9-26	1361-1363	SF	substance[67]|place	giv[67]|new	_	_
9-27	1364-1365	)	substance[67]	giv[67]	_	_
9-28	1366-1367	,	substance[67]	giv[67]	_	_
9-29	1368-1371	and	substance[67]	giv[67]	_	_
9-30	1372-1390	glycosaminoglycans	substance[67]|person	giv[67]|new	_	_
9-31	1391-1392	(	_	_	_	_
9-32	1393-1397	GAGs	abstract	new	_	_
9-33	1398-1399	)	_	_	_	_
9-34	1400-1401	.	_	_	_	_

#Text=Chitosan ( CS ) , a natural polymer obtained from the partial deacetylation of chitin , is one of the most common biopolymers on earth .
10-1	1402-1410	Chitosan	substance	giv	coref	10-20[85_0]
10-2	1411-1412	(	_	_	_	_
10-3	1413-1415	CS	substance	new	appos	10-6[81_0]
10-4	1416-1417	)	_	_	_	_
10-5	1418-1419	,	_	_	_	_
10-6	1420-1421	a	substance[81]	giv[81]	coref	12-1[0_81]
10-7	1422-1429	natural	substance[81]	giv[81]	_	_
10-8	1430-1437	polymer	substance[81]	giv[81]	_	_
10-9	1438-1446	obtained	substance[81]	giv[81]	_	_
10-10	1447-1451	from	substance[81]	giv[81]	_	_
10-11	1452-1455	the	substance[81]|substance[82]	giv[81]|new[82]	_	_
10-12	1456-1463	partial	substance[81]|substance[82]	giv[81]|new[82]	_	_
10-13	1464-1477	deacetylation	substance[81]|substance[82]	giv[81]|new[82]	_	_
10-14	1478-1480	of	substance[81]|substance[82]	giv[81]|new[82]	_	_
10-15	1481-1487	chitin	substance[81]|substance[82]|substance	giv[81]|new[82]|new	_	_
10-16	1488-1489	,	_	_	_	_
10-17	1490-1492	is	_	_	_	_
10-18	1493-1496	one	object[84]	new[84]	ana	11-1[0_84]
10-19	1497-1499	of	object[84]	new[84]	_	_
10-20	1500-1503	the	object[84]|substance[85]	new[84]|giv[85]	coref	19-13[0_85]
10-21	1504-1508	most	object[84]|substance[85]	new[84]|giv[85]	_	_
10-22	1509-1515	common	object[84]|substance[85]	new[84]|giv[85]	_	_
10-23	1516-1527	biopolymers	object[84]|substance[85]	new[84]|giv[85]	_	_
10-24	1528-1530	on	object[84]|substance[85]	new[84]|giv[85]	_	_
10-25	1531-1536	earth	object[84]|substance[85]|place	new[84]|giv[85]|new	_	_
10-26	1537-1538	.	_	_	_	_

#Text=It is present in the shells of crustaceans such as crab and shrimp .
11-1	1539-1541	It	object	giv	_	_
11-2	1542-1544	is	_	_	_	_
11-3	1545-1552	present	_	_	_	_
11-4	1553-1555	in	_	_	_	_
11-5	1556-1559	the	object[88]	new[88]	_	_
11-6	1560-1566	shells	object[88]	new[88]	_	_
11-7	1567-1569	of	object[88]	new[88]	_	_
11-8	1570-1581	crustaceans	object[88]|animal[89]	new[88]|new[89]	_	_
11-9	1582-1586	such	object[88]|animal[89]	new[88]|new[89]	_	_
11-10	1587-1589	as	object[88]|animal[89]	new[88]|new[89]	_	_
11-11	1590-1594	crab	object[88]|animal[89]|animal	new[88]|new[89]|new	_	_
11-12	1595-1598	and	object[88]|animal[89]	new[88]|new[89]	_	_
11-13	1599-1605	shrimp	object[88]|animal[89]|animal	new[88]|new[89]|new	_	_
11-14	1606-1607	.	_	_	_	_

#Text=CS has many desirable properties for tissue engineering such as biocompatibility , non-toxicity , and biodegradability .
12-1	1608-1610	CS	substance	giv	coref	13-1
12-2	1611-1614	has	_	_	_	_
12-3	1615-1619	many	abstract[93]	giv[93]	coref	17-14[159_93]
12-4	1620-1629	desirable	abstract[93]	giv[93]	_	_
12-5	1630-1640	properties	abstract[93]	giv[93]	_	_
12-6	1641-1644	for	abstract[93]	giv[93]	_	_
12-7	1645-1651	tissue	abstract[93]|object|abstract[95]	giv[93]|giv|new[95]	coref|coref	14-6|14-5[128_95]
12-8	1652-1663	engineering	abstract[93]|abstract[95]	giv[93]|new[95]	_	_
12-9	1664-1668	such	abstract[93]	giv[93]	_	_
12-10	1669-1671	as	abstract[93]	giv[93]	_	_
12-11	1672-1688	biocompatibility	abstract[93]|abstract	giv[93]|new	coref	15-19[141_0]
12-12	1689-1690	,	abstract[93]	giv[93]	_	_
12-13	1691-1703	non-toxicity	abstract[93]|abstract	giv[93]|new	_	_
12-14	1704-1705	,	abstract[93]	giv[93]	_	_
12-15	1706-1709	and	abstract[93]	giv[93]	_	_
12-16	1710-1726	biodegradability	abstract[93]|abstract	giv[93]|giv	_	_
12-17	1727-1728	.	_	_	_	_

#Text=CS was used in several tissue-engineering applications involving bone , cartilage , liver , tendons , ligaments and nerves , wound healing , separation membranes , blood anticoagulants , contact lenses , controlled release of drugs , fat-sequestering agent , hydrogel preparations , and food packaging material .
13-1	1729-1731	CS	substance	giv	coref	14-1
13-2	1732-1735	was	_	_	_	_
13-3	1736-1740	used	_	_	_	_
13-4	1741-1743	in	_	_	_	_
13-5	1744-1751	several	abstract[101]	new[101]	coref	19-15[182_101]
13-6	1752-1770	tissue-engineering	object|abstract[101]	new|new[101]	_	_
13-7	1771-1783	applications	abstract[101]	new[101]	_	_
13-8	1784-1793	involving	abstract[101]	new[101]	_	_
13-9	1794-1798	bone	abstract[101]|object	new[101]|new	coref	14-5
13-10	1799-1800	,	abstract[101]	new[101]	_	_
13-11	1801-1810	cartilage	abstract[101]|object	new[101]|new	_	_
13-12	1811-1812	,	abstract[101]	new[101]	_	_
13-13	1813-1818	liver	abstract[101]|object	new[101]|new	_	_
13-14	1819-1820	,	abstract[101]	new[101]	_	_
13-15	1821-1828	tendons	abstract[101]|object	new[101]|new	_	_
13-16	1829-1830	,	abstract[101]	new[101]	_	_
13-17	1831-1840	ligaments	abstract[101]|object	new[101]|new	_	_
13-18	1841-1844	and	abstract[101]	new[101]	_	_
13-19	1845-1851	nerves	abstract[101]|object	new[101]|new	_	_
13-20	1852-1853	,	abstract[101]	new[101]	_	_
13-21	1854-1859	wound	abstract[101]|abstract|event[109]	new[101]|new|new[109]	_	_
13-22	1860-1867	healing	abstract[101]|event[109]	new[101]|new[109]	_	_
13-23	1868-1869	,	abstract[101]	new[101]	_	_
13-24	1870-1880	separation	abstract[101]|abstract|object[111]	new[101]|new|new[111]	_	_
13-25	1881-1890	membranes	abstract[101]|object[111]	new[101]|new[111]	_	_
13-26	1891-1892	,	abstract[101]	new[101]	_	_
13-27	1893-1898	blood	abstract[101]|substance|event[116]	new[101]|new|new[116]	_	_
13-28	1899-1913	anticoagulants	abstract[101]|substance|event[116]	new[101]|new|new[116]	_	_
13-29	1914-1915	,	abstract[101]|event[116]	new[101]|new[116]	_	_
13-30	1916-1923	contact	abstract[101]|abstract|object[115]|event[116]	new[101]|new|new[115]|new[116]	_	_
13-31	1924-1930	lenses	abstract[101]|object[115]|event[116]	new[101]|new[115]|new[116]	_	_
13-32	1931-1932	,	abstract[101]|event[116]	new[101]|new[116]	_	_
13-33	1933-1943	controlled	abstract[101]|event[116]	new[101]|new[116]	_	_
13-34	1944-1951	release	abstract[101]|event[116]	new[101]|new[116]	_	_
13-35	1952-1954	of	abstract[101]|event[116]	new[101]|new[116]	_	_
13-36	1955-1960	drugs	abstract[101]|event[116]|substance	new[101]|new[116]|new	_	_
13-37	1961-1962	,	abstract[101]	new[101]	_	_
13-38	1963-1979	fat-sequestering	abstract[101]|abstract|substance[119]	new[101]|new|new[119]	_	_
13-39	1980-1985	agent	abstract[101]|substance[119]	new[101]|new[119]	_	_
13-40	1986-1987	,	abstract[101]	new[101]	_	_
13-41	1988-1996	hydrogel	abstract[101]|substance|substance[121]	new[101]|new|new[121]	_	_
13-42	1997-2009	preparations	abstract[101]|substance[121]	new[101]|new[121]	_	_
13-43	2010-2011	,	abstract[101]	new[101]	_	_
13-44	2012-2015	and	abstract[101]	new[101]	_	_
13-45	2016-2020	food	abstract[101]|substance|substance[124]	new[101]|new|new[124]	_	_
13-46	2021-2030	packaging	abstract[101]|abstract|substance[124]	new[101]|new|new[124]	_	_
13-47	2031-2039	material	abstract[101]|substance[124]	new[101]|new[124]	_	_
13-48	2040-2041	.	_	_	_	_

#Text=CS was evaluated for bone tissue engineering ( BTE ) with good cell adhesion and proliferation observed .
14-1	2042-2044	CS	substance	giv	coref	15-1
14-2	2045-2048	was	_	_	_	_
14-3	2049-2058	evaluated	_	_	_	_
14-4	2059-2062	for	_	_	_	_
14-5	2063-2067	bone	object|abstract[128]	giv|giv[128]	appos	14-9[0_128]
14-6	2068-2074	tissue	object|abstract[128]	giv|giv[128]	coref	19-17
14-7	2075-2086	engineering	abstract[128]	giv[128]	_	_
14-8	2087-2088	(	_	_	_	_
14-9	2089-2092	BTE	abstract	giv	coref	15-17
14-10	2093-2094	)	_	_	_	_
14-11	2095-2099	with	_	_	_	_
14-12	2100-2104	good	abstract[131]|abstract[132]	giv[131]|giv[132]	coref|coref	30-34[260_131]|30-34[261_132]
14-13	2105-2109	cell	place|abstract[131]|abstract[132]	giv|giv[131]|giv[132]	coref	15-22
14-14	2110-2118	adhesion	abstract[131]|abstract[132]	giv[131]|giv[132]	_	_
14-15	2119-2122	and	abstract[132]	giv[132]	_	_
14-16	2123-2136	proliferation	abstract[132]|event[133]	giv[132]|giv[133]	coref	15-22[143_133]
14-17	2137-2145	observed	abstract[132]|event[133]	giv[132]|giv[133]	_	_
14-18	2146-2147	.	_	_	_	_

#Text=CS composites with different materials such as ceramics , nanofillers , and polymers were evaluated for BTE with excellent biocompatibility and cell proliferation results .
15-1	2148-2150	CS	substance|object[135]	giv|new[135]	coref|coref	26-8|26-8[231_135]
15-2	2151-2161	composites	object[135]	new[135]	_	_
15-3	2162-2166	with	object[135]	new[135]	_	_
15-4	2167-2176	different	object[135]|substance[136]	new[135]|giv[136]	coref	15-13[0_136]
15-5	2177-2186	materials	object[135]|substance[136]	new[135]|giv[136]	_	_
15-6	2187-2191	such	object[135]|substance[136]	new[135]|giv[136]	_	_
15-7	2192-2194	as	object[135]|substance[136]	new[135]|giv[136]	_	_
15-8	2195-2203	ceramics	object[135]|substance[136]|object	new[135]|giv[136]|new	_	_
15-9	2204-2205	,	object[135]|substance[136]	new[135]|giv[136]	_	_
15-10	2206-2217	nanofillers	object[135]|substance[136]|object	new[135]|giv[136]|new	coref	20-1[185_0]
15-11	2218-2219	,	object[135]|substance[136]	new[135]|giv[136]	_	_
15-12	2220-2223	and	object[135]|substance[136]	new[135]|giv[136]	_	_
15-13	2224-2232	polymers	object[135]|substance[136]|substance	new[135]|giv[136]|giv	coref	18-8[170_0]
15-14	2233-2237	were	_	_	_	_
15-15	2238-2247	evaluated	_	_	_	_
15-16	2248-2251	for	_	_	_	_
15-17	2252-2255	BTE	abstract	giv	coref	16-21
15-18	2256-2260	with	_	_	_	_
15-19	2261-2270	excellent	abstract[141]	giv[141]	ana	16-1[0_141]
15-20	2271-2287	biocompatibility	abstract[141]	giv[141]	_	_
15-21	2288-2291	and	_	_	_	_
15-22	2292-2296	cell	place|event[143]|abstract[144]	giv|giv[143]|new[144]	coref|coref|coref	16-16|30-37[0_143]|32-1[280_144]
15-23	2297-2310	proliferation	event[143]|abstract[144]	giv[143]|new[144]	_	_
15-24	2311-2318	results	abstract[144]	new[144]	_	_
15-25	2319-2320	.	_	_	_	_

#Text=It was recognized that amine and hydroxyl groups facilitate the addition of side groups for cell incorporation and recognition in BTE .
16-1	2321-2323	It	abstract	giv	coref	20-20[188_0]
16-2	2324-2327	was	_	_	_	_
16-3	2328-2338	recognized	_	_	_	_
16-4	2339-2343	that	_	_	_	_
16-5	2344-2349	amine	substance|person[148]	new|new[148]	coref	16-13[151_148]
16-6	2350-2353	and	person[148]	new[148]	_	_
16-7	2354-2362	hydroxyl	organization|person[148]	new|new[148]	_	_
16-8	2363-2369	groups	person[148]	new[148]	_	_
16-9	2370-2380	facilitate	_	_	_	_
16-10	2381-2384	the	event[149]	new[149]	_	_
16-11	2385-2393	addition	event[149]	new[149]	_	_
16-12	2394-2396	of	event[149]	new[149]	_	_
16-13	2397-2401	side	event[149]|abstract|person[151]	new[149]|new|giv[151]	coref	22-15[210_151]
16-14	2402-2408	groups	event[149]|person[151]	new[149]|giv[151]	_	_
16-15	2409-2412	for	event[149]|person[151]	new[149]|giv[151]	_	_
16-16	2413-2417	cell	event[149]|person[151]|place|event[153]	new[149]|giv[151]|giv|new[153]	coref	24-8[222_0]
16-17	2418-2431	incorporation	event[149]|person[151]|event[153]	new[149]|giv[151]|new[153]	_	_
16-18	2432-2435	and	event[149]|person[151]	new[149]|giv[151]	_	_
16-19	2436-2447	recognition	event[149]|person[151]|abstract[154]	new[149]|giv[151]|new[154]	coref	30-41[263_154]
16-20	2448-2450	in	event[149]|person[151]|abstract[154]	new[149]|giv[151]|new[154]	_	_
16-21	2451-2454	BTE	event[149]|person[151]|abstract[154]|abstract	new[149]|giv[151]|new[154]|giv	ana	17-8
16-22	2455-2456	.	_	_	_	_

#Text=However , like many other polysaccharides , it presents some disadvantages such as poor mechanical properties , poor solubility in conventional solvents , and poor stability in physiological media due to the high amount of hydrogen bonding .
17-1	2457-2464	However	_	_	_	_
17-2	2465-2466	,	_	_	_	_
17-3	2467-2471	like	_	_	_	_
17-4	2472-2476	many	substance[156]	new[156]	_	_
17-5	2477-2482	other	substance[156]	new[156]	_	_
17-6	2483-2498	polysaccharides	substance[156]	new[156]	_	_
17-7	2499-2500	,	_	_	_	_
17-8	2501-2503	it	abstract	giv	coref	19-17[184_0]
17-9	2504-2512	presents	_	_	_	_
17-10	2513-2517	some	abstract[158]	new[158]	coref	18-16[173_158]
17-11	2518-2531	disadvantages	abstract[158]	new[158]	_	_
17-12	2532-2536	such	abstract[158]	new[158]	_	_
17-13	2537-2539	as	abstract[158]	new[158]	_	_
17-14	2540-2544	poor	abstract[158]|abstract[159]|abstract[160]	new[158]|giv[159]|giv[160]	coref|coref	17-14[160_159]|27-1[233_160]
17-15	2545-2555	mechanical	abstract[158]|abstract[159]|abstract[160]	new[158]|giv[159]|giv[160]	_	_
17-16	2556-2566	properties	abstract[158]|abstract[159]|abstract[160]	new[158]|giv[159]|giv[160]	_	_
17-17	2567-2568	,	abstract[158]|abstract[160]	new[158]|giv[160]	_	_
17-18	2569-2573	poor	abstract[158]|abstract[160]|substance[161]	new[158]|giv[160]|new[161]	_	_
17-19	2574-2584	solubility	abstract[158]|abstract[160]|substance[161]	new[158]|giv[160]|new[161]	_	_
17-20	2585-2587	in	abstract[158]|abstract[160]|substance[161]	new[158]|giv[160]|new[161]	_	_
17-21	2588-2600	conventional	abstract[158]|abstract[160]|substance[161]|substance[162]	new[158]|giv[160]|new[161]|new[162]	_	_
17-22	2601-2609	solvents	abstract[158]|abstract[160]|substance[161]|substance[162]	new[158]|giv[160]|new[161]|new[162]	_	_
17-23	2610-2611	,	abstract[158]|abstract[160]	new[158]|giv[160]	_	_
17-24	2612-2615	and	abstract[158]|abstract[160]	new[158]|giv[160]	_	_
17-25	2616-2620	poor	abstract[158]|abstract[160]|abstract[163]	new[158]|giv[160]|new[163]	coref	20-13[187_163]
17-26	2621-2630	stability	abstract[158]|abstract[160]|abstract[163]	new[158]|giv[160]|new[163]	_	_
17-27	2631-2633	in	abstract[158]|abstract[160]|abstract[163]	new[158]|giv[160]|new[163]	_	_
17-28	2634-2647	physiological	abstract[158]|abstract[160]|abstract[163]|substance[164]	new[158]|giv[160]|new[163]|new[164]	_	_
17-29	2648-2653	media	abstract[158]|abstract[160]|abstract[163]|substance[164]	new[158]|giv[160]|new[163]|new[164]	_	_
17-30	2654-2657	due	abstract[158]|abstract[160]|abstract[163]	new[158]|giv[160]|new[163]	_	_
17-31	2658-2660	to	abstract[158]|abstract[160]|abstract[163]	new[158]|giv[160]|new[163]	_	_
17-32	2661-2664	the	abstract[158]|abstract[160]|abstract[163]|abstract[165]	new[158]|giv[160]|new[163]|new[165]	_	_
17-33	2665-2669	high	abstract[158]|abstract[160]|abstract[163]|abstract[165]	new[158]|giv[160]|new[163]|new[165]	_	_
17-34	2670-2676	amount	abstract[158]|abstract[160]|abstract[163]|abstract[165]	new[158]|giv[160]|new[163]|new[165]	_	_
17-35	2677-2679	of	abstract[158]|abstract[160]|abstract[163]|abstract[165]	new[158]|giv[160]|new[163]|new[165]	_	_
17-36	2680-2688	hydrogen	abstract[158]|abstract[160]|abstract[163]|abstract[165]|substance|abstract[167]	new[158]|giv[160]|new[163]|new[165]|new|new[167]	_	_
17-37	2689-2696	bonding	abstract[158]|abstract[160]|abstract[163]|abstract[165]|abstract[167]	new[158]|giv[160]|new[163]|new[165]|new[167]	_	_
17-38	2697-2698	.	_	_	_	_

#Text=Many studies addressed the physicochemical attributes of nanocomposite polymers thanks to their effectiveness in overcoming the disadvantages of naturally occurring polymers .
18-1	2699-2703	Many	abstract[168]	new[168]	coref	30-13[256_168]
18-2	2704-2711	studies	abstract[168]	new[168]	_	_
18-3	2712-2721	addressed	_	_	_	_
18-4	2722-2725	the	abstract[169]	new[169]	_	_
18-5	2726-2741	physicochemical	abstract[169]	new[169]	_	_
18-6	2742-2752	attributes	abstract[169]	new[169]	_	_
18-7	2753-2755	of	abstract[169]	new[169]	_	_
18-8	2756-2769	nanocomposite	abstract[169]|substance[170]	new[169]|giv[170]	ana	18-12[0_170]
18-9	2770-2778	polymers	abstract[169]|substance[170]	new[169]|giv[170]	_	_
18-10	2779-2785	thanks	_	_	_	_
18-11	2786-2788	to	_	_	_	_
18-12	2789-2794	their	substance|abstract[172]	giv|new[172]	coref	18-19[174_0]
18-13	2795-2808	effectiveness	abstract[172]	new[172]	_	_
18-14	2809-2811	in	abstract[172]	new[172]	_	_
18-15	2812-2822	overcoming	abstract[172]	new[172]	_	_
18-16	2823-2826	the	abstract[172]|abstract[173]	new[172]|giv[173]	_	_
18-17	2827-2840	disadvantages	abstract[172]|abstract[173]	new[172]|giv[173]	_	_
18-18	2841-2843	of	abstract[172]|abstract[173]	new[172]|giv[173]	_	_
18-19	2844-2853	naturally	abstract[172]|abstract[173]|substance[174]	new[172]|giv[173]|giv[174]	_	_
18-20	2854-2863	occurring	abstract[172]|abstract[173]|substance[174]	new[172]|giv[173]|giv[174]	_	_
18-21	2864-2872	polymers	abstract[172]|abstract[173]|substance[174]	new[172]|giv[173]|giv[174]	_	_
18-22	2873-2874	.	_	_	_	_

#Text=Our group investigated the use of nanocomposites based on graphene oxide and chitosan for applications in tissue engineering .
19-1	2875-2878	Our	person|organization[176]	acc|new[176]	_	_
19-2	2879-2884	group	organization[176]	new[176]	_	_
19-3	2885-2897	investigated	_	_	_	_
19-4	2898-2901	the	abstract[177]	new[177]	_	_
19-5	2902-2905	use	abstract[177]	new[177]	_	_
19-6	2906-2908	of	abstract[177]	new[177]	_	_
19-7	2909-2923	nanocomposites	abstract[177]|object[178]	new[177]|new[178]	coref	20-23[189_178]
19-8	2924-2929	based	abstract[177]|object[178]	new[177]|new[178]	_	_
19-9	2930-2932	on	abstract[177]|object[178]	new[177]|new[178]	_	_
19-10	2933-2941	graphene	abstract[177]|object[178]|abstract|substance[180]	new[177]|new[178]|new|new[180]	_	_
19-11	2942-2947	oxide	abstract[177]|object[178]|substance[180]	new[177]|new[178]|new[180]	_	_
19-12	2948-2951	and	abstract[177]|object[178]	new[177]|new[178]	_	_
19-13	2952-2960	chitosan	abstract[177]|object[178]|substance	new[177]|new[178]|giv	coref	20-25
19-14	2961-2964	for	abstract[177]|object[178]	new[177]|new[178]	_	_
19-15	2965-2977	applications	abstract[177]|object[178]|abstract[182]	new[177]|new[178]|giv[182]	coref	23-5[215_182]
19-16	2978-2980	in	abstract[177]|object[178]|abstract[182]	new[177]|new[178]|giv[182]	_	_
19-17	2981-2987	tissue	abstract[177]|object[178]|abstract[182]|object|abstract[184]	new[177]|new[178]|giv[182]|giv|giv[184]	coref|coref	32-23|32-23[287_184]
19-18	2988-2999	engineering	abstract[177]|object[178]|abstract[182]|abstract[184]	new[177]|new[178]|giv[182]|giv[184]	_	_
19-19	3000-3001	.	_	_	_	_

#Text=Even with the nanofillers , there is still a need to achieve better mechanical and thermal stability combined with higher biocompatibility in nanocomposites of chitosan and carbon nanomaterials .
20-1	3002-3006	Even	object[185]	giv[185]	_	_
20-2	3007-3011	with	object[185]	giv[185]	_	_
20-3	3012-3015	the	object[185]	giv[185]	_	_
20-4	3016-3027	nanofillers	object[185]	giv[185]	_	_
20-5	3028-3029	,	_	_	_	_
20-6	3030-3035	there	_	_	_	_
20-7	3036-3038	is	_	_	_	_
20-8	3039-3044	still	_	_	_	_
20-9	3045-3046	a	abstract[186]	new[186]	_	_
20-10	3047-3051	need	abstract[186]	new[186]	_	_
20-11	3052-3054	to	abstract[186]	new[186]	_	_
20-12	3055-3062	achieve	abstract[186]	new[186]	_	_
20-13	3063-3069	better	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-14	3070-3080	mechanical	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-15	3081-3084	and	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-16	3085-3092	thermal	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-17	3093-3102	stability	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-18	3103-3111	combined	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-19	3112-3116	with	abstract[186]|abstract[187]	new[186]|giv[187]	_	_
20-20	3117-3123	higher	abstract[186]|abstract[187]|abstract[188]	new[186]|giv[187]|giv[188]	coref	33-14[0_188]
20-21	3124-3140	biocompatibility	abstract[186]|abstract[187]|abstract[188]	new[186]|giv[187]|giv[188]	_	_
20-22	3141-3143	in	abstract[186]|abstract[187]|abstract[188]	new[186]|giv[187]|giv[188]	_	_
20-23	3144-3158	nanocomposites	abstract[186]|abstract[187]|abstract[188]|object[189]	new[186]|giv[187]|giv[188]|giv[189]	_	_
20-24	3159-3161	of	abstract[186]|abstract[187]|abstract[188]|object[189]	new[186]|giv[187]|giv[188]|giv[189]	_	_
20-25	3162-3170	chitosan	abstract[186]|abstract[187]|abstract[188]|object[189]|substance|substance[191]|object[193]	new[186]|giv[187]|giv[188]|giv[189]|giv|giv[191]|new[193]	coref|coref	20-25[191_0]|27-18[0_191]
20-26	3171-3174	and	abstract[186]|abstract[187]|abstract[188]|object[189]|substance[191]|object[193]	new[186]|giv[187]|giv[188]|giv[189]|giv[191]|new[193]	_	_
20-27	3175-3181	carbon	abstract[186]|abstract[187]|abstract[188]|object[189]|substance[191]|substance|object[193]	new[186]|giv[187]|giv[188]|giv[189]|giv[191]|new|new[193]	coref	21-22
20-28	3182-3195	nanomaterials	abstract[186]|abstract[187]|abstract[188]|object[189]|object[193]	new[186]|giv[187]|giv[188]|giv[189]|new[193]	_	_
20-29	3196-3197	.	_	_	_	_

#Text=Carbon nano-onions ( CNOs ) are multi-shell fullerenes of 5 to 10 nm , discovered by Ugarte in 1992 upon impacting carbon nanostructures with an electron beam through a TEM experiment .
21-1	3198-3204	Carbon	person|abstract[195]	new|new[195]	coref	21-7[197_195]
21-2	3205-3216	nano-onions	abstract[195]	new[195]	_	_
21-3	3217-3218	(	_	_	_	_
21-4	3219-3223	CNOs	abstract	new	coref	22-6
21-5	3224-3225	)	_	_	_	_
21-6	3226-3229	are	_	_	_	_
21-7	3230-3241	multi-shell	abstract[197]	giv[197]	_	_
21-8	3242-3252	fullerenes	abstract[197]	giv[197]	_	_
21-9	3253-3255	of	abstract[197]	giv[197]	_	_
21-10	3256-3257	5	abstract[197]|abstract[198]	giv[197]|new[198]	_	_
21-11	3258-3260	to	abstract[197]|abstract[198]	giv[197]|new[198]	_	_
21-12	3261-3263	10	abstract[197]|abstract[198]	giv[197]|new[198]	_	_
21-13	3264-3266	nm	abstract[197]|abstract[198]	giv[197]|new[198]	_	_
21-14	3267-3268	,	abstract[197]	giv[197]	_	_
21-15	3269-3279	discovered	abstract[197]	giv[197]	_	_
21-16	3280-3282	by	abstract[197]	giv[197]	_	_
21-17	3283-3289	Ugarte	abstract[197]|person	giv[197]|new	_	_
21-18	3290-3292	in	abstract[197]	giv[197]	_	_
21-19	3293-3297	1992	abstract[197]|time	giv[197]|new	_	_
21-20	3298-3302	upon	_	_	_	_
21-21	3303-3312	impacting	_	_	_	_
21-22	3313-3319	carbon	substance|object[202]	giv|new[202]	_	_
21-23	3320-3334	nanostructures	object[202]	new[202]	_	_
21-24	3335-3339	with	_	_	_	_
21-25	3340-3342	an	object[204]	new[204]	_	_
21-26	3343-3351	electron	substance|object[204]	new|new[204]	_	_
21-27	3352-3356	beam	object[204]	new[204]	_	_
21-28	3357-3364	through	_	_	_	_
21-29	3365-3366	a	event[206]	new[206]	_	_
21-30	3367-3370	TEM	place|event[206]	new|new[206]	_	_
21-31	3371-3381	experiment	event[206]	new[206]	_	_
21-32	3382-3383	.	_	_	_	_

#Text=For the chemical derivatization of CNOs , various synthetic routes were applied , introducing new functional groups that increase their application possibilities .
22-1	3384-3387	For	_	_	_	_
22-2	3388-3391	the	abstract[207]	new[207]	_	_
22-3	3392-3400	chemical	abstract[207]	new[207]	_	_
22-4	3401-3415	derivatization	abstract[207]	new[207]	_	_
22-5	3416-3418	of	abstract[207]	new[207]	_	_
22-6	3419-3423	CNOs	abstract[207]|abstract	new[207]|giv	coref	24-1
22-7	3424-3425	,	_	_	_	_
22-8	3426-3433	various	person[209]	new[209]	ana	22-20[0_209]
22-9	3434-3443	synthetic	person[209]	new[209]	_	_
22-10	3444-3450	routes	person[209]	new[209]	_	_
22-11	3451-3455	were	_	_	_	_
22-12	3456-3463	applied	_	_	_	_
22-13	3464-3465	,	_	_	_	_
22-14	3466-3477	introducing	_	_	_	_
22-15	3478-3481	new	person[210]	giv[210]	_	_
22-16	3482-3492	functional	person[210]	giv[210]	_	_
22-17	3493-3499	groups	person[210]	giv[210]	_	_
22-18	3500-3504	that	person[210]	giv[210]	_	_
22-19	3505-3513	increase	person[210]	giv[210]	_	_
22-20	3514-3519	their	person[210]|person|abstract[213]	giv[210]|giv|new[213]	ana	25-1
22-21	3520-3531	application	person[210]|abstract|abstract[213]	giv[210]|new|new[213]	coref	32-19[285_0]
22-22	3532-3545	possibilities	person[210]|abstract[213]	giv[210]|new[213]	_	_
22-23	3546-3547	.	_	_	_	_

#Text=Some potential uses include optical applications , catalysis , and gas storage .
23-1	3548-3552	Some	abstract[214]	new[214]	_	_
23-2	3553-3562	potential	abstract[214]	new[214]	_	_
23-3	3563-3567	uses	abstract[214]	new[214]	_	_
23-4	3568-3575	include	_	_	_	_
23-5	3576-3583	optical	abstract[215]|abstract[216]	giv[215]|giv[216]	coref|coref	23-5[216_215]|24-6[223_216]
23-6	3584-3596	applications	abstract[215]|abstract[216]	giv[215]|giv[216]	_	_
23-7	3597-3598	,	abstract[216]	giv[216]	_	_
23-8	3599-3608	catalysis	abstract[216]|abstract	giv[216]|new	_	_
23-9	3609-3610	,	abstract[216]	giv[216]	_	_
23-10	3611-3614	and	abstract[216]	giv[216]	_	_
23-11	3615-3618	gas	abstract[216]|substance|abstract[219]	giv[216]|new|new[219]	_	_
23-12	3619-3626	storage	abstract[216]|abstract[219]	giv[216]|new[219]	_	_
23-13	3627-3628	.	_	_	_	_

#Text=CNOs are also useful in photovoltaic and fuel cell applications .
24-1	3629-3633	CNOs	abstract	giv	coref	27-8
24-2	3634-3637	are	_	_	_	_
24-3	3638-3642	also	_	_	_	_
24-4	3643-3649	useful	_	_	_	_
24-5	3650-3652	in	_	_	_	_
24-6	3653-3665	photovoltaic	abstract[223]	giv[223]	coref	28-14[249_223]
24-7	3666-3669	and	abstract[223]	giv[223]	_	_
24-8	3670-3674	fuel	substance|place[222]|abstract[223]	new|giv[222]|giv[223]	coref	30-34[0_222]
24-9	3675-3679	cell	place[222]|abstract[223]	giv[222]|giv[223]	_	_
24-10	3680-3692	applications	abstract[223]	giv[223]	_	_
24-11	3693-3694	.	_	_	_	_

#Text=They demonstrated a superior lubrication ability compared to conventional lubricants .
25-1	3695-3699	They	person	giv	_	_
25-2	3700-3712	demonstrated	_	_	_	_
25-3	3713-3714	a	abstract[226]	new[226]	_	_
25-4	3715-3723	superior	abstract[226]	new[226]	_	_
25-5	3724-3735	lubrication	substance|abstract[226]	new|new[226]	_	_
25-6	3736-3743	ability	abstract[226]	new[226]	_	_
25-7	3744-3752	compared	abstract[226]	new[226]	_	_
25-8	3753-3755	to	abstract[226]	new[226]	_	_
25-9	3756-3768	conventional	abstract[226]|substance[227]	new[226]|new[227]	_	_
25-10	3769-3779	lubricants	abstract[226]|substance[227]	new[226]|new[227]	_	_
25-11	3780-3781	.	_	_	_	_

#Text=However , there are few reports of CS and CNO composites in the literature .
26-1	3782-3789	However	_	_	_	_
26-2	3790-3791	,	_	_	_	_
26-3	3792-3797	there	_	_	_	_
26-4	3798-3801	are	_	_	_	_
26-5	3802-3805	few	abstract[228]	new[228]	_	_
26-6	3806-3813	reports	abstract[228]	new[228]	_	_
26-7	3814-3816	of	abstract[228]	new[228]	_	_
26-8	3817-3819	CS	abstract[228]|substance|object[231]	new[228]|giv|giv[231]	coref|coref	27-5[234_231]|27-20
26-9	3820-3823	and	abstract[228]|object[231]	new[228]|giv[231]	_	_
26-10	3824-3827	CNO	abstract[228]|abstract|object[231]	new[228]|new|giv[231]	_	_
26-11	3828-3838	composites	abstract[228]|object[231]	new[228]|giv[231]	_	_
26-12	3839-3841	in	abstract[228]|object[231]	new[228]|giv[231]	_	_
26-13	3842-3845	the	abstract[228]|object[231]|abstract[232]	new[228]|giv[231]|new[232]	coref	28-4[244_232]
26-14	3846-3856	literature	abstract[228]|object[231]|abstract[232]	new[228]|giv[231]|new[232]	_	_
26-15	3857-3858	.	_	_	_	_

#Text=The electrochemical properties of composites consisting of CNOs and poly(diallyl dimethylammonium chloride ) ( PDDA ) or chitosan ( CS ) were reported .
27-1	3859-3862	The	abstract[233]	giv[233]	_	_
27-2	3863-3878	electrochemical	abstract[233]	giv[233]	_	_
27-3	3879-3889	properties	abstract[233]	giv[233]	_	_
27-4	3890-3892	of	abstract[233]	giv[233]	_	_
27-5	3893-3903	composites	abstract[233]|object[234]	giv[233]|giv[234]	_	_
27-6	3904-3914	consisting	abstract[233]|object[234]	giv[233]|giv[234]	_	_
27-7	3915-3917	of	abstract[233]|object[234]	giv[233]|giv[234]	_	_
27-8	3918-3922	CNOs	abstract[233]|object[234]|abstract|abstract[236]	giv[233]|giv[234]|giv|giv[236]	coref|coref	27-8[236_0]|29-12[0_236]
27-9	3923-3926	and	abstract[233]|object[234]|abstract[236]	giv[233]|giv[234]|giv[236]	_	_
27-10	3927-3939	poly(diallyl	abstract[233]|object[234]|abstract[236]|substance|substance[239]	giv[233]|giv[234]|giv[236]|new|new[239]	appos	27-15[0_239]
27-11	3940-3956	dimethylammonium	abstract[233]|object[234]|abstract[236]|substance|substance[239]	giv[233]|giv[234]|giv[236]|new|new[239]	_	_
27-12	3957-3965	chloride	abstract[233]|object[234]|abstract[236]|substance[239]	giv[233]|giv[234]|giv[236]|new[239]	_	_
27-13	3966-3967	)	abstract[233]|object[234]|abstract[236]	giv[233]|giv[234]|giv[236]	_	_
27-14	3968-3969	(	abstract[233]|object[234]|abstract[236]	giv[233]|giv[234]|giv[236]	_	_
27-15	3970-3974	PDDA	abstract[233]|object[234]|abstract[236]|substance	giv[233]|giv[234]|giv[236]|giv	_	_
27-16	3975-3976	)	abstract[233]|object[234]|abstract[236]	giv[233]|giv[234]|giv[236]	_	_
27-17	3977-3979	or	abstract[233]|object[234]|abstract[236]	giv[233]|giv[234]|giv[236]	_	_
27-18	3980-3988	chitosan	abstract[233]|object[234]|abstract[236]|substance	giv[233]|giv[234]|giv[236]|giv	_	_
27-19	3989-3990	(	_	_	_	_
27-20	3991-3993	CS	substance	giv	coref	28-8
27-21	3994-3995	)	_	_	_	_
27-22	3996-4000	were	_	_	_	_
27-23	4001-4009	reported	_	_	_	_
27-24	4010-4011	.	_	_	_	_

#Text=The lack of literature regarding nanocomposites of CS and oxidized ( ox-)CNOs for biomedical applications is evident .
28-1	4012-4015	The	abstract[243]	new[243]	_	_
28-2	4016-4020	lack	abstract[243]	new[243]	_	_
28-3	4021-4023	of	abstract[243]	new[243]	_	_
28-4	4024-4034	literature	abstract[243]|abstract[244]	new[243]|giv[244]	_	_
28-5	4035-4044	regarding	abstract[243]|abstract[244]	new[243]|giv[244]	_	_
28-6	4045-4059	nanocomposites	abstract[243]|abstract[244]|object[245]|substance[246]	new[243]|giv[244]|new[245]|new[246]	ana|coref	30-1[0_246]|32-12[283_245]
28-7	4060-4062	of	abstract[243]|abstract[244]|object[245]|substance[246]	new[243]|giv[244]|new[245]|new[246]	_	_
28-8	4063-4065	CS	abstract[243]|abstract[244]|object[245]|substance[246]|substance	new[243]|giv[244]|new[245]|new[246]|giv	_	_
28-9	4066-4069	and	abstract[243]|abstract[244]|substance[246]	new[243]|giv[244]|new[246]	_	_
28-10	4070-4078	oxidized	abstract[243]|abstract[244]|substance[246]|object[248]	new[243]|giv[244]|new[246]|new[248]	_	_
28-11	4079-4080	(	abstract[243]|abstract[244]|substance[246]|object[248]	new[243]|giv[244]|new[246]|new[248]	_	_
28-12	4081-4089	ox-)CNOs	abstract[243]|abstract[244]|substance[246]|object[248]	new[243]|giv[244]|new[246]|new[248]	_	_
28-13	4090-4093	for	abstract[243]|abstract[244]|substance[246]|object[248]	new[243]|giv[244]|new[246]|new[248]	_	_
28-14	4094-4104	biomedical	abstract[243]|abstract[244]|substance[246]|object[248]|abstract[249]	new[243]|giv[244]|new[246]|new[248]|giv[249]	_	_
28-15	4105-4117	applications	abstract[243]|abstract[244]|substance[246]|object[248]|abstract[249]	new[243]|giv[244]|new[246]|new[248]|giv[249]	_	_
28-16	4118-4120	is	_	_	_	_
28-17	4121-4128	evident	_	_	_	_
28-18	4129-4130	.	_	_	_	_

#Text=Very few studies were carried out to determine the cytotoxicity of CNOs .
29-1	4131-4135	Very	abstract[250]	new[250]	_	_
29-2	4136-4139	few	abstract[250]	new[250]	_	_
29-3	4140-4147	studies	abstract[250]	new[250]	_	_
29-4	4148-4152	were	_	_	_	_
29-5	4153-4160	carried	_	_	_	_
29-6	4161-4164	out	_	_	_	_
29-7	4165-4167	to	_	_	_	_
29-8	4168-4177	determine	_	_	_	_
29-9	4178-4181	the	abstract[251]	new[251]	_	_
29-10	4182-4194	cytotoxicity	abstract[251]	new[251]	_	_
29-11	4195-4197	of	abstract[251]	new[251]	_	_
29-12	4198-4202	CNOs	abstract[251]|abstract	new[251]|giv	_	_
29-13	4203-4204	.	_	_	_	_

#Text=They were even used for the treatment of cancer ; however , many more studies are still required to show whether they are toxic or if , on the contrary , they promote cell adhesion and proliferation , while facilitating the recognition and permanence of scaffolds in animal tissues without immune responses .
30-1	4205-4209	They	substance	giv	ana	30-22
30-2	4210-4214	were	_	_	_	_
30-3	4215-4219	even	_	_	_	_
30-4	4220-4224	used	_	_	_	_
30-5	4225-4228	for	_	_	_	_
30-6	4229-4232	the	abstract[254]	new[254]	_	_
30-7	4233-4242	treatment	abstract[254]	new[254]	_	_
30-8	4243-4245	of	abstract[254]	new[254]	_	_
30-9	4246-4252	cancer	abstract[254]|abstract	new[254]|new	_	_
30-10	4253-4254	;	_	_	_	_
30-11	4255-4262	however	_	_	_	_
30-12	4263-4264	,	_	_	_	_
30-13	4265-4269	many	abstract[256]	giv[256]	coref	33-14[293_256]
30-14	4270-4274	more	abstract[256]	giv[256]	_	_
30-15	4275-4282	studies	abstract[256]	giv[256]	_	_
30-16	4283-4286	are	_	_	_	_
30-17	4287-4292	still	_	_	_	_
30-18	4293-4301	required	_	_	_	_
30-19	4302-4304	to	_	_	_	_
30-20	4305-4309	show	_	_	_	_
30-21	4310-4317	whether	_	_	_	_
30-22	4318-4322	they	substance	giv	ana	30-32
30-23	4323-4326	are	_	_	_	_
30-24	4327-4332	toxic	_	_	_	_
30-25	4333-4335	or	_	_	_	_
30-26	4336-4338	if	_	_	_	_
30-27	4339-4340	,	_	_	_	_
30-28	4341-4343	on	_	_	_	_
30-29	4344-4347	the	_	_	_	_
30-30	4348-4356	contrary	_	_	_	_
30-31	4357-4358	,	_	_	_	_
30-32	4359-4363	they	substance	giv	_	_
30-33	4364-4371	promote	_	_	_	_
30-34	4372-4376	cell	place|abstract[260]|abstract[261]	giv|giv[260]|giv[261]	_	_
30-35	4377-4385	adhesion	abstract[260]|abstract[261]	giv[260]|giv[261]	_	_
30-36	4386-4389	and	abstract[261]	giv[261]	_	_
30-37	4390-4403	proliferation	abstract[261]|event	giv[261]|giv	_	_
30-38	4404-4405	,	_	_	_	_
30-39	4406-4411	while	_	_	_	_
30-40	4412-4424	facilitating	_	_	_	_
30-41	4425-4428	the	abstract[263]	giv[263]	_	_
30-42	4429-4440	recognition	abstract[263]	giv[263]	_	_
30-43	4441-4444	and	_	_	_	_
30-44	4445-4455	permanence	event[264]	new[264]	_	_
30-45	4456-4458	of	event[264]	new[264]	_	_
30-46	4459-4468	scaffolds	event[264]|object	new[264]|new	_	_
30-47	4469-4471	in	event[264]	new[264]	_	_
30-48	4472-4478	animal	event[264]|person|object[267]	new[264]|new|new[267]	ana	31-8[0_267]
30-49	4479-4486	tissues	event[264]|object[267]	new[264]|new[267]	_	_
30-50	4487-4494	without	event[264]|object[267]	new[264]|new[267]	_	_
30-51	4495-4501	immune	event[264]|object[267]|abstract[268]	new[264]|new[267]|new[268]	_	_
30-52	4502-4511	responses	event[264]|object[267]|abstract[268]	new[264]|new[267]|new[268]	_	_
30-53	4512-4513	.	_	_	_	_

#Text=There is a lack of information on their characterization including the physical , chemical , and mechanical evaluation of nanocomposite films based on CS/poly(vinyl alcohol ) ( PVA)/ox-CNO , together with biological tests in vitro and in vivo .
31-1	4514-4519	There	_	_	_	_
31-2	4520-4522	is	_	_	_	_
31-3	4523-4524	a	abstract[269]	new[269]	_	_
31-4	4525-4529	lack	abstract[269]	new[269]	_	_
31-5	4530-4532	of	abstract[269]	new[269]	_	_
31-6	4533-4544	information	abstract[269]|abstract[270]	new[269]|new[270]	coref	32-9[282_270]
31-7	4545-4547	on	abstract[269]|abstract[270]	new[269]|new[270]	_	_
31-8	4548-4553	their	abstract[269]|abstract[270]|object|abstract[272]	new[269]|new[270]|giv|new[272]	_	_
31-9	4554-4570	characterization	abstract[269]|abstract[270]|abstract[272]	new[269]|new[270]|new[272]	_	_
31-10	4571-4580	including	abstract[269]|abstract[270]	new[269]|new[270]	_	_
31-11	4581-4584	the	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-12	4585-4593	physical	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-13	4594-4595	,	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-14	4596-4604	chemical	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-15	4605-4606	,	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-16	4607-4610	and	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-17	4611-4621	mechanical	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-18	4622-4632	evaluation	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-19	4633-4635	of	abstract[269]|abstract[270]|abstract[273]	new[269]|new[270]|new[273]	_	_
31-20	4636-4649	nanocomposite	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	coref	33-6[289_274]
31-21	4650-4655	films	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	_	_
31-22	4656-4661	based	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	_	_
31-23	4662-4664	on	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	_	_
31-24	4665-4678	CS/poly(vinyl	abstract[269]|abstract[270]|abstract[273]|object[274]|substance[275]	new[269]|new[270]|new[273]|new[274]|new[275]	_	_
31-25	4679-4686	alcohol	abstract[269]|abstract[270]|abstract[273]|object[274]|substance[275]	new[269]|new[270]|new[273]|new[274]|new[275]	_	_
31-26	4687-4688	)	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	_	_
31-27	4689-4690	(	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	_	_
31-28	4691-4702	PVA)/ox-CNO	abstract[269]|abstract[270]|abstract[273]|object[274]|substance	new[269]|new[270]|new[273]|new[274]|new	_	_
31-29	4703-4704	,	abstract[269]|abstract[270]|abstract[273]|object[274]	new[269]|new[270]|new[273]|new[274]	_	_
31-30	4705-4713	together	abstract[269]|abstract[270]|abstract[273]|object[274]|abstract[277]	new[269]|new[270]|new[273]|new[274]|new[277]	_	_
31-31	4714-4718	with	abstract[269]|abstract[270]|abstract[273]|object[274]|abstract[277]	new[269]|new[270]|new[273]|new[274]|new[277]	_	_
31-32	4719-4729	biological	abstract[269]|abstract[270]|abstract[273]|object[274]|abstract[277]	new[269]|new[270]|new[273]|new[274]|new[277]	_	_
31-33	4730-4735	tests	abstract[269]|abstract[270]|abstract[273]|object[274]|abstract[277]	new[269]|new[270]|new[273]|new[274]|new[277]	_	_
31-34	4736-4738	in	abstract[269]|abstract[270]|abstract[273]|object[274]|abstract[277]	new[269]|new[270]|new[273]|new[274]|new[277]	_	_
31-35	4739-4744	vitro	abstract[269]|abstract[270]|abstract[273]|object[274]|abstract[277]|organization	new[269]|new[270]|new[273]|new[274]|new[277]|new	_	_
31-36	4745-4748	and	_	_	_	_
31-37	4749-4751	in	_	_	_	_
31-38	4752-4756	vivo	abstract	new	_	_
31-39	4757-4758	.	_	_	_	_

#Text=The results of this investigation will allow collecting toxicological information for these nanocomposites , as well as evaluating their possible application in tissue engineering .
32-1	4759-4762	The	abstract[280]	giv[280]	_	_
32-2	4763-4770	results	abstract[280]	giv[280]	_	_
32-3	4771-4773	of	abstract[280]	giv[280]	_	_
32-4	4774-4778	this	abstract[280]|abstract[281]	giv[280]|new[281]	_	_
32-5	4779-4792	investigation	abstract[280]|abstract[281]	giv[280]|new[281]	_	_
32-6	4793-4797	will	_	_	_	_
32-7	4798-4803	allow	_	_	_	_
32-8	4804-4814	collecting	_	_	_	_
32-9	4815-4828	toxicological	abstract[282]	giv[282]	_	_
32-10	4829-4840	information	abstract[282]	giv[282]	_	_
32-11	4841-4844	for	abstract[282]	giv[282]	_	_
32-12	4845-4850	these	abstract[282]|object[283]	giv[282]|giv[283]	ana	32-19[0_283]
32-13	4851-4865	nanocomposites	abstract[282]|object[283]	giv[282]|giv[283]	_	_
32-14	4866-4867	,	_	_	_	_
32-15	4868-4870	as	_	_	_	_
32-16	4871-4875	well	_	_	_	_
32-17	4876-4878	as	_	_	_	_
32-18	4879-4889	evaluating	_	_	_	_
32-19	4890-4895	their	object|abstract[285]	giv|giv[285]	_	_
32-20	4896-4904	possible	abstract[285]	giv[285]	_	_
32-21	4905-4916	application	abstract[285]	giv[285]	_	_
32-22	4917-4919	in	abstract[285]	giv[285]	_	_
32-23	4920-4926	tissue	abstract[285]|object|abstract[287]	giv[285]|giv|giv[287]	_	_
32-24	4927-4938	engineering	abstract[285]|abstract[287]	giv[285]|giv[287]	_	_
32-25	4939-4940	.	_	_	_	_

#Text=Therefore , this research investigates nanocomposite films of PVA/CS reinforced with ox-CNOs for biocompatibility studies at 90 days of subdermal implantation in biomodel skin .
33-1	4941-4950	Therefore	_	_	_	_
33-2	4951-4952	,	_	_	_	_
33-3	4953-4957	this	abstract[288]	new[288]	_	_
33-4	4958-4966	research	abstract[288]	new[288]	_	_
33-5	4967-4979	investigates	_	_	_	_
33-6	4980-4993	nanocomposite	object[289]	giv[289]	_	_
33-7	4994-4999	films	object[289]	giv[289]	_	_
33-8	5000-5002	of	object[289]	giv[289]	_	_
33-9	5003-5009	PVA/CS	object[289]|substance[290]	giv[289]|new[290]	_	_
33-10	5010-5020	reinforced	object[289]|substance[290]	giv[289]|new[290]	_	_
33-11	5021-5025	with	object[289]|substance[290]	giv[289]|new[290]	_	_
33-12	5026-5033	ox-CNOs	object[289]|substance[290]|abstract	giv[289]|new[290]|new	_	_
33-13	5034-5037	for	object[289]|substance[290]	giv[289]|new[290]	_	_
33-14	5038-5054	biocompatibility	object[289]|substance[290]|abstract|abstract[293]	giv[289]|new[290]|giv|giv[293]	_	_
33-15	5055-5062	studies	object[289]|substance[290]|abstract[293]	giv[289]|new[290]|giv[293]	_	_
33-16	5063-5065	at	object[289]|substance[290]|abstract[293]	giv[289]|new[290]|giv[293]	_	_
33-17	5066-5068	90	object[289]|substance[290]|abstract[293]|time[294]	giv[289]|new[290]|giv[293]|new[294]	_	_
33-18	5069-5073	days	object[289]|substance[290]|abstract[293]|time[294]	giv[289]|new[290]|giv[293]|new[294]	_	_
33-19	5074-5076	of	object[289]|substance[290]|abstract[293]|time[294]	giv[289]|new[290]|giv[293]|new[294]	_	_
33-20	5077-5086	subdermal	object[289]|substance[290]|abstract[293]|time[294]|abstract[295]	giv[289]|new[290]|giv[293]|new[294]|new[295]	_	_
33-21	5087-5099	implantation	object[289]|substance[290]|abstract[293]|time[294]|abstract[295]	giv[289]|new[290]|giv[293]|new[294]|new[295]	_	_
33-22	5100-5102	in	object[289]|substance[290]|abstract[293]|time[294]|abstract[295]	giv[289]|new[290]|giv[293]|new[294]|new[295]	_	_
33-23	5103-5111	biomodel	object[289]|substance[290]|abstract[293]|time[294]|abstract[295]|object[296]	giv[289]|new[290]|giv[293]|new[294]|new[295]|new[296]	_	_
33-24	5112-5116	skin	object[289]|substance[290]|abstract[293]|time[294]|abstract[295]|object[296]	giv[289]|new[290]|giv[293]|new[294]|new[295]|new[296]	_	_
33-25	5117-5118	.	_	_	_	_
